Developmental Outcomes of Aicardi Goutières Syndrome

Laura Adang, Francesco Gavazzi, Micaela De Simone, Elisa Fazzi, Jessica Galli, Jamie Koh, Julia Kramer-Golinkoff, Valentina De Giorgis, Simona Orcesi, Kyle Peer, Nicole Ulrick, Sarah Woidill, Justine Shults, Adeline Vanderver

Research output: Contribution to journalArticle

Abstract

Aicardi Goutières syndrome is a monogenic interferonopathy caused by abnormalities in the intracellular nucleic acid sensing machinery (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, or IFIH1). Most individuals affected by Aicardi Goutières syndrome exhibit some degree of neurologic impairment, from spastic paraparesis with relatively preserved cognition to tetraparesis and severe intellectual disability. Because of this heterogeneity, it is important to fully characterize the developmental trajectory in Aicardi Goutières syndrome. To characterize the clinical presentation in Aicardi Goutières syndrome, early features were collected from an international cohort of children (n = 100) with genetically confirmed Aicardi Goutières syndrome. There was a heterogeneous age of onset, with overlapping clusters of presenting symptoms: altered mental status, systemic inflammatory symptoms, and acute neurologic disability. Next, we created genotype-specific developmental milestone acquisition curves. Individuals with microcephaly or TREX1-related Aicardi Goutières syndrome secondary were the most severely affected and less likely to reach milestones, including head control, sitting, and nonspecific mama/dada. Individuals affected by SAMHD1, IFIH1, and ADAR attained the most advanced milestones, with 44% achieving verbal communication and 31% independently ambulating. Retrospective function scales (Gross Motor Function Classification System, Manual Ability Classification System, and Communication Function Classification System) demonstrated that two-thirds of the Aicardi Goutières syndrome population are severely affected. Our results suggest multifactorial influences on developmental trajectory, including a strong contribution from genotype. Further studies are needed to identify the additional factors that influence overall outcomes to better counsel families and to design clinical trials with appropriate clinical endpoints.

Original languageEnglish
Pages (from-to)7-16
Number of pages10
JournalJournal of Child Neurology
Early online dateSep 27 2019
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Aicardi Syndrome
Communication
Genotype
Spastic Paraparesis
Microcephaly
Aptitude
Neurologic Manifestations
Age of Onset
Intellectual Disability
Cognition
Nucleic Acids
Nervous System
Head
Clinical Trials

Cite this

Adang, L., Gavazzi, F., De Simone, M., Fazzi, E., Galli, J., Koh, J., ... Vanderver, A. (2020). Developmental Outcomes of Aicardi Goutières Syndrome. Journal of Child Neurology, 7-16. https://doi.org/10.1177/0883073819870944

Developmental Outcomes of Aicardi Goutières Syndrome. / Adang, Laura; Gavazzi, Francesco; De Simone, Micaela; Fazzi, Elisa; Galli, Jessica; Koh, Jamie; Kramer-Golinkoff, Julia; De Giorgis, Valentina; Orcesi, Simona; Peer, Kyle; Ulrick, Nicole; Woidill, Sarah; Shults, Justine; Vanderver, Adeline.

In: Journal of Child Neurology, 01.2020, p. 7-16.

Research output: Contribution to journalArticle

Adang, L, Gavazzi, F, De Simone, M, Fazzi, E, Galli, J, Koh, J, Kramer-Golinkoff, J, De Giorgis, V, Orcesi, S, Peer, K, Ulrick, N, Woidill, S, Shults, J & Vanderver, A 2020, 'Developmental Outcomes of Aicardi Goutières Syndrome', Journal of Child Neurology, pp. 7-16. https://doi.org/10.1177/0883073819870944
Adang L, Gavazzi F, De Simone M, Fazzi E, Galli J, Koh J et al. Developmental Outcomes of Aicardi Goutières Syndrome. Journal of Child Neurology. 2020 Jan;7-16. https://doi.org/10.1177/0883073819870944
Adang, Laura ; Gavazzi, Francesco ; De Simone, Micaela ; Fazzi, Elisa ; Galli, Jessica ; Koh, Jamie ; Kramer-Golinkoff, Julia ; De Giorgis, Valentina ; Orcesi, Simona ; Peer, Kyle ; Ulrick, Nicole ; Woidill, Sarah ; Shults, Justine ; Vanderver, Adeline. / Developmental Outcomes of Aicardi Goutières Syndrome. In: Journal of Child Neurology. 2020 ; pp. 7-16.
@article{354c06dae59241f1b45b58f5aa4780c1,
title = "Developmental Outcomes of Aicardi Gouti{\`e}res Syndrome",
abstract = "Aicardi Gouti{\`e}res syndrome is a monogenic interferonopathy caused by abnormalities in the intracellular nucleic acid sensing machinery (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, or IFIH1). Most individuals affected by Aicardi Gouti{\`e}res syndrome exhibit some degree of neurologic impairment, from spastic paraparesis with relatively preserved cognition to tetraparesis and severe intellectual disability. Because of this heterogeneity, it is important to fully characterize the developmental trajectory in Aicardi Gouti{\`e}res syndrome. To characterize the clinical presentation in Aicardi Gouti{\`e}res syndrome, early features were collected from an international cohort of children (n = 100) with genetically confirmed Aicardi Gouti{\`e}res syndrome. There was a heterogeneous age of onset, with overlapping clusters of presenting symptoms: altered mental status, systemic inflammatory symptoms, and acute neurologic disability. Next, we created genotype-specific developmental milestone acquisition curves. Individuals with microcephaly or TREX1-related Aicardi Gouti{\`e}res syndrome secondary were the most severely affected and less likely to reach milestones, including head control, sitting, and nonspecific mama/dada. Individuals affected by SAMHD1, IFIH1, and ADAR attained the most advanced milestones, with 44{\%} achieving verbal communication and 31{\%} independently ambulating. Retrospective function scales (Gross Motor Function Classification System, Manual Ability Classification System, and Communication Function Classification System) demonstrated that two-thirds of the Aicardi Gouti{\`e}res syndrome population are severely affected. Our results suggest multifactorial influences on developmental trajectory, including a strong contribution from genotype. Further studies are needed to identify the additional factors that influence overall outcomes to better counsel families and to design clinical trials with appropriate clinical endpoints.",
author = "Laura Adang and Francesco Gavazzi and {De Simone}, Micaela and Elisa Fazzi and Jessica Galli and Jamie Koh and Julia Kramer-Golinkoff and {De Giorgis}, Valentina and Simona Orcesi and Kyle Peer and Nicole Ulrick and Sarah Woidill and Justine Shults and Adeline Vanderver",
year = "2020",
month = "1",
doi = "10.1177/0883073819870944",
language = "English",
pages = "7--16",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Developmental Outcomes of Aicardi Goutières Syndrome

AU - Adang, Laura

AU - Gavazzi, Francesco

AU - De Simone, Micaela

AU - Fazzi, Elisa

AU - Galli, Jessica

AU - Koh, Jamie

AU - Kramer-Golinkoff, Julia

AU - De Giorgis, Valentina

AU - Orcesi, Simona

AU - Peer, Kyle

AU - Ulrick, Nicole

AU - Woidill, Sarah

AU - Shults, Justine

AU - Vanderver, Adeline

PY - 2020/1

Y1 - 2020/1

N2 - Aicardi Goutières syndrome is a monogenic interferonopathy caused by abnormalities in the intracellular nucleic acid sensing machinery (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, or IFIH1). Most individuals affected by Aicardi Goutières syndrome exhibit some degree of neurologic impairment, from spastic paraparesis with relatively preserved cognition to tetraparesis and severe intellectual disability. Because of this heterogeneity, it is important to fully characterize the developmental trajectory in Aicardi Goutières syndrome. To characterize the clinical presentation in Aicardi Goutières syndrome, early features were collected from an international cohort of children (n = 100) with genetically confirmed Aicardi Goutières syndrome. There was a heterogeneous age of onset, with overlapping clusters of presenting symptoms: altered mental status, systemic inflammatory symptoms, and acute neurologic disability. Next, we created genotype-specific developmental milestone acquisition curves. Individuals with microcephaly or TREX1-related Aicardi Goutières syndrome secondary were the most severely affected and less likely to reach milestones, including head control, sitting, and nonspecific mama/dada. Individuals affected by SAMHD1, IFIH1, and ADAR attained the most advanced milestones, with 44% achieving verbal communication and 31% independently ambulating. Retrospective function scales (Gross Motor Function Classification System, Manual Ability Classification System, and Communication Function Classification System) demonstrated that two-thirds of the Aicardi Goutières syndrome population are severely affected. Our results suggest multifactorial influences on developmental trajectory, including a strong contribution from genotype. Further studies are needed to identify the additional factors that influence overall outcomes to better counsel families and to design clinical trials with appropriate clinical endpoints.

AB - Aicardi Goutières syndrome is a monogenic interferonopathy caused by abnormalities in the intracellular nucleic acid sensing machinery (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, or IFIH1). Most individuals affected by Aicardi Goutières syndrome exhibit some degree of neurologic impairment, from spastic paraparesis with relatively preserved cognition to tetraparesis and severe intellectual disability. Because of this heterogeneity, it is important to fully characterize the developmental trajectory in Aicardi Goutières syndrome. To characterize the clinical presentation in Aicardi Goutières syndrome, early features were collected from an international cohort of children (n = 100) with genetically confirmed Aicardi Goutières syndrome. There was a heterogeneous age of onset, with overlapping clusters of presenting symptoms: altered mental status, systemic inflammatory symptoms, and acute neurologic disability. Next, we created genotype-specific developmental milestone acquisition curves. Individuals with microcephaly or TREX1-related Aicardi Goutières syndrome secondary were the most severely affected and less likely to reach milestones, including head control, sitting, and nonspecific mama/dada. Individuals affected by SAMHD1, IFIH1, and ADAR attained the most advanced milestones, with 44% achieving verbal communication and 31% independently ambulating. Retrospective function scales (Gross Motor Function Classification System, Manual Ability Classification System, and Communication Function Classification System) demonstrated that two-thirds of the Aicardi Goutières syndrome population are severely affected. Our results suggest multifactorial influences on developmental trajectory, including a strong contribution from genotype. Further studies are needed to identify the additional factors that influence overall outcomes to better counsel families and to design clinical trials with appropriate clinical endpoints.

U2 - 10.1177/0883073819870944

DO - 10.1177/0883073819870944

M3 - Article

C2 - 31559893

SP - 7

EP - 16

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

ER -